MaxCyte’s flow electroporation is driving the next generation of cell-based medicines. Used in the discovery, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.
Maximizing Transient Protein Production
Introduction Companies are turning to transient production of proteins to accelerate timelines, gain quick access to protein for early go-no go decisions, delay stable cell line generation, and reduce costs. Expanding the role of transient protein ... Continued
Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic Development
Reducing drug development timelines and cost is a goal that we hear repeatedly in the industry. One area where timing is crucial is in reaching a go/no go decision on a therapeutic candidate and efficient ... Continued